Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- How to Invest in QE's Twilight
- RTI: Fed Keeps QE Pace Unchanged
- ETFs on the Move After Bernanke's Press Conference
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- Your Next Stock Should Be Making New Highs
- PFP 6/20: I Am FED UP!
- AWS 6/19: Will Bernanke Clarify Matters Today?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORT.COM | SPRT | 3.75% |
| UNISYS | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MTN CO | GMCR | 3.13% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Immunomedics Inc.’s (IMMU - Snapshot Report) fourth quarter fiscal 2011 (ended June 30) earnings of $0.03 surpassed the year-ago earnings of $0.01. The Zacks Consensus Estimate hinted at a loss of $0.06. Earnings in the quarter were boosted by higher revenues.
Quarterly Results
Revenues in the final quarter of fiscal 2011 came in at $11.1 million compared to the year-ago figure of $6.1 million. Revenues blew past the Zacks Consensus Estimate of $3 million.
The year-over-year jump was primarily attributable to the receipt of a $10.0 million milestone payment from partner Nycomed for the development of veltuzumab in the rheumatoid arthritis indication. Immunomedics received $5 million from Nycomed in the year-ago quarter.
Revenues from product sales at Immunomedics climbed approximately 81% to $0.9 million in the final quarter of fiscal 2011. Revenues from research and development accounted for the balance.
The rise in revenues was partially mitigated by higher research and development (R&D) expenses. The increase in R&D expenses in the final quarter of fiscal 2011 was attributable to lower expense reimbursements under the partnership with Nycomed coupled with increased clinical trial expenses.
Annual Results
For fiscal 2011, Immunomedics suffered a loss of $0.20 per share as opposed to the earnings of $0.49 in fiscal 2010. The Zacks Consensus loss estimate for fiscal 2011 was $0.28. The loss suffered by the company in fiscal 2011 was attributable to a massive fall in revenues.
Revenues in fiscal 2011 plummeted 76% to $14.7 million. The decline was attributable to the absence of upfront license fee revenues from Immunomedics’ agreements with UCB (UCBJF) and Nycomed. Fiscal 2010 revenues included $31.1 million and $14.5 million as upfront payments from UCB and Nycomed respectively. The Zacks Consensus Estimate for fiscal 2011 was $7 million.
Moreover, increased R&D expenses also contributed to the loss suffered by Immunomedics in fiscal 2011.
Our Recommendation
We currently have a Neutral recommendation on Immunomedics. The stock carries a Zacks #3 Rank (Neutral rating) in the short-run.
Get the full Snapshot Report on IMMU - FREE
Get the full on UCBJF - FREE